Exagen Q4 Earnings Call Highlights

Core Insights - Exagen reported record revenue of $66.6 million for full-year 2025, marking a nearly 20% increase from 2024, driven by higher testing volume and ASP expansion [1] - The company has implemented operational changes since 2022, including customer service upgrades, clinical record collection improvements, and a streamlined R&D portfolio [2][3] - Exagen's strategy focuses on enhancing diagnostic precision for autoimmune diseases, contrasting with longer diagnostic timelines in conditions like lupus and rheumatoid arthritis [3] Financial Performance - For 2026, Exagen guided revenue between $70 million and $73 million, anticipating high single-digit volume growth and low single-digit ASP growth [5][16] - The trailing 12-month ASP increased to approximately $441, up about 7% from $411, despite experiencing ASP pressure in the second half of 2025 due to a client billing disruption [6][7] - The company reported a gross margin of just over 58% for 2025, down from about 60% in 2024, attributed to ASP pressure [13] Operational Developments - Exagen expanded its sales organization to 45 territories, up from about 40, and reported a testing volume of 137,000 AVISE CTD tests in 2025 [6][10] - The company has launched three sets of innovative biomarkers in the clinic within an 18-month period and is working on additional clinical offerings [2][18] - Management highlighted ongoing efforts to improve market access, including advocacy from the American College of Rheumatology [11] Cash Position and Expenses - Exagen ended 2025 with over $32 million in cash and cash equivalents, with a total of more than $43 million in cash plus accounts receivable [15] - Operating expenses for 2025 were $53 million, reflecting a 13% year-over-year increase, with SG&A at $47 million and R&D at just over $6 million [14] Future Outlook - The company aims to reach breakeven Adjusted EBITDA and positive cash generation at an ~$80 million revenue run rate, with a focus on ASP expansion and cost optimization [5][17] - Exagen plans to formalize a product launch cadence, intending to introduce one new product each year, with a focus on myositis and other autoimmune conditions [18]